BioClinica Inc, a U.S. pharmaceutical contract research organization owned by buyout firm JLL Partners, is exploring a sale that could value it at as much as $1.3 billion, including debt, according to people familiar with the matter.
The Newtown, Pennsylvania-based company has hired investment bank Jefferies LLC to run an auction for the company, the people said this week, declining to be identified because the discussions are private.
JLL Partners declined to comment. Jefferies and BioClinica did not immediately respond to requests for comment.
The sale process highlights a wave of dealmaking activity that has overtaken the pharmaceutical services sector in recent months, with some of the largest players, including InVentiv Health Inc and Capsugel Inc, exploring an outright sale or an initial public offering, according to reports by Reuters.
Last year, another JLL Partners investment, Patheon, announced plans for an IPO. It is one of the largest contract manufacturing companies in the pharmaceutical industry.
In 2013, JLL Partners acquired BioClinica, which was at the time a publicly traded company, for an equity value of $123 million.
In the ensuing years, the buyout firm rapidly scaled up BioClinica through a series of acquisitions, including most recently with the purchase of specialty clinical trial services firm Synowledge.
BioClinica’s profits have grown as a result, with annual earnings before interest, taxes depreciation and amortization now approaching $100 million, according to the sources.
BioClinica assists pharmaceutical companies in clinical trials, and has expertise in technologies that focus on clinical research data and analytics. It supports over 17,000 clinical trial sites in 90 countries.
By Carl O’Donnell
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
